<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03359863</url>
  </required_header>
  <id_info>
    <org_study_id>16-20710</org_study_id>
    <nct_id>NCT03359863</nct_id>
  </id_info>
  <brief_title>Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction</brief_title>
  <acronym>PIRCLAD</acronym>
  <official_title>Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite advances in lung transplantation, the median survival remains only 55% at 5 years.
      The main limitation to long term survival is the development of chronic lung allograft
      dysfunction. In approximately 30% of cases, chronic lung allograft dysfunction has a
      restrictive phenotype (RCLAD) characterized by fibrosis with rapid progression to respiratory
      failure. Approximately 60% of patients with RCLAD die within one year, as currently there are
      no therapies available.

      RCLAD, like Idiopathic Pulmonary Fibrosis (IPF), is characterized by fibroblast
      proliferation, extracellular matrix deposition, and architectural distortion leading to
      progressive lung scarring and death. Given their similarities, there is keen interest in the
      international transplant community to investigate whether the anti-fibrotic drug pirfenidone
      can slow the progression of RCLAD as it does of IPF. Pirfenidone has been proved to be safe
      and effective in patients with IPF, and is approved by the Food and Drug Administration.

      This protocol will evaluate the safety and tolerability of pirfenidone in lung transplant
      recipients with RCLAD. Transplant recipients take carefully adjusted immunosuppressive
      medications for life to prevent rejection of the allograft. Current literature suggests the
      dose of tacrolimus, the main anti-rejection drug, may need to be adjusted when taken in
      combination with pirfenidone. The investigators will assess the side effects of pirfenidone
      in combination with the immunosuppressive regimen and determine the magnitude of the
      adjustment in tacrolimus dose. The results of this pilot study will provide the foundation
      for a multicenter randomized control trial to evaluate the efficacy of pirfenidone in slowing
      the progression of RCLAD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite advances in lung transplantation, median survival remains only 55% at 5 years. The
      primary cause of death is chronic lung allograft dysfunction (CLAD), occurring in 43% of
      recipients at 5 years. Recently, it has been recognized that CLAD can have an obstructive
      (BOS) or a restrictive (RCLAD) phenotype, also known as restrictive allograft syndrome (RAS),
      and that both may coexist. These phenotypes differ not only in their spirometric,
      radiographic and histologic features but also in their rates of progression and survival.
      Thus, there is a critical need to find therapies other than re-transplantation, which remains
      the only effective therapeutic option and explore the pathobiology driving RCLAD.

      RCLAD shares features with Idiopathic Pulmonary Fibrosis (IPF), including its progressive and
      lethal course, extracellular matrix deposition, architectural distortion, fibroblast
      proliferation, and short telomeres in lung epithelial cells. These common features suggest
      RCLAD and IPF may share molecular pathogenesis. As a result, some have explored using FDA
      approved anti-fibrotic medications for IPF in RCLAD in case reports.

      This proposal aims to gather the preliminary data needed to design a multicenter randomized
      controlled trial (RCT) of pirfenidone for RCLAD. To do so, the investigators first need
      evidence of tolerability, to understand drug interactions with the immunosuppressive regimen
      used to maintain allograft function and early evidence that pirfenidone may slow FVC decline
      and radiographic progression in RCLAD.

      Evidence that pirfenidone is well tolerated in transplant recipients and that it slows the
      progression of RCLAD would be paradigm shifting. Further, identifying subjects at risk for
      RCLAD before the onset of spirometric changes would allow to start therapeutic interventions
      sooner, maximizing their benefit. Finding biomarkers that predict response to pirfenidone
      would identify patients most likely to benefit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of pirfenidone</measure>
    <time_frame>From initiation of pirfenidone until discontinuation or until 52 weeks, which ever comes first.</time_frame>
    <description>The primary outcome will be the number of subjects that discontinue pirfenidone due to a treatment emergent adverse event (TEAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tacrolimus dose change</measure>
    <time_frame>From initiation of pirfenidone until discontinuation or until 52 weeks, which ever comes first.</time_frame>
    <description>The outcome will be the ratio of tacrolimus-on-pirfenidone to tacrolimus-off-pirfenidone corrected for the subject's specific steady-state tacrolimus concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) decline</measure>
    <time_frame>Every 3 months starting at initiation of pirfenidone until 52 weeks.</time_frame>
    <description>The investigators will evaluate change in FVC every 3 months after initiation of pirfenidone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression</measure>
    <time_frame>From RCLAD onset and in the follow up CT scans performed as part of routine clinical care for 52 weeks.</time_frame>
    <description>The investigators will evaluate fibrosis scores on chest CT at RCLAD onset and in the follow up CT scans performed as part of routine clinical care.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Restrictive Chronic Lung Allograft Dysfunction</condition>
  <condition>Lung Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Pirfenidone as part of treatment for their restrictive chronic lung allograft dysfunction (RCLAD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Subjects will receive pirfenidone for 52 weeks, titrated to 2403 mg/day (3 capsules, 3× daily)</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject who underwent bilateral lung transplantation at University of California San
             Francisco (UCSF) and have a diagnosis of RCLAD based on the International Heart and
             Lung Transplant (ISHLT) classification. The diagnosis of RCLAD is based on spirometry
             (Forced Expiratory Volume in 1 second (FEV1) ≤ 80% and FVC ≤ 80% of best
             post-transplant baseline) and CT scan (e.g. pleuroparenchymal fibroelastosis)
             findings.

        Exclusion Criteria:

          -  FVC decline related to non-RCLAD causes (e.g. pulmonary edema, pleural effusion, etc).

          -  Patients with any severe comorbidity complicating RCLAD which might determine their
             prognosis and functional level (e.g. active malignant disease) within the last 12
             months

          -  Patients who have resumed smoking after transplantation

          -  Renal insufficiency (creatinine clearance &lt; 30 ml/min calculated by the CKD-Epi
             formula)

          -  Total bilirubin above the upper limit of the normal range (ULN)

          -  Aspartate or alanine aminotransferase (AST or ALT) &gt; 3 times the ULN.

          -  Known allergy of hypersensitivity to Pirfenidone

          -  Pregnancy

          -  Ongoing use or expected use of any of the following therapies:

          -  Strong inhibitors of CYP1A2 (e.g. fluvoxamine or enoxacin).

          -  Moderate inhibitors of CAYP1A2 (e. g. mexiletine, thiabendazole, or
             phenylpropanolamine). Ciprofloxacin will be allowed only at doses equal or less than
             500 mg BID.

          -  Inability to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aida A Venado Estrada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aida A Venado Estrada, MD</last_name>
    <phone>415-443-1977</phone>
    <email>aida.venado@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pavan Shrestha</last_name>
    <phone>(415) 476-4539</phone>
    <email>pavan.shrestha@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aida A Venado Estrada, MD</last_name>
      <phone>415-443-1977</phone>
      <email>aida.venado@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pavan Shrestha, BS</last_name>
      <phone>415-476-4539</phone>
      <email>pavan.shrestha@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Aida A Venado Estrada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Valapour M, Skeans MA, Smith JM, Edwards LB, Cherikh WS, Callahan ER, Israni AK, Snyder JJ, Kasiske BL. Lung. Am J Transplant. 2016 Jan;16 Suppl 2:141-68. doi: 10.1111/ajt.13671.</citation>
    <PMID>26755267</PMID>
  </reference>
  <reference>
    <citation>Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant. 2014 Feb;33(2):127-33. doi: 10.1016/j.healun.2013.10.022. Epub 2013 Oct 24.</citation>
    <PMID>24374027</PMID>
  </reference>
  <reference>
    <citation>Saito T, Horie M, Sato M, Nakajima D, Shoushtarizadeh H, Binnie M, Azad S, Hwang DM, Machuca TN, Waddell TK, Singer LG, Cypel M, Liu M, Paul NS, Keshavjee S. Low-dose computed tomography volumetry for subtyping chronic lung allograft dysfunction. J Heart Lung Transplant. 2016 Jan;35(1):59-66. doi: 10.1016/j.healun.2015.07.005. Epub 2015 Aug 13.</citation>
    <PMID>26342441</PMID>
  </reference>
  <reference>
    <citation>Pakhale SS, Hadjiliadis D, Howell DN, Palmer SM, Gutierrez C, Waddell TK, Chaparro C, Davis RD, Keshavjee S, Hutcheon MA, Singer LG. Upper lobe fibrosis: a novel manifestation of chronic allograft dysfunction in lung transplantation. J Heart Lung Transplant. 2005 Sep;24(9):1260-8.</citation>
    <PMID>16143243</PMID>
  </reference>
  <reference>
    <citation>Ofek E, Sato M, Saito T, Wagnetz U, Roberts HC, Chaparro C, Waddell TK, Singer LG, Hutcheon MA, Keshavjee S, Hwang DM. Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis. Mod Pathol. 2013 Mar;26(3):350-6. doi: 10.1038/modpathol.2012.171. Epub 2012 Sep 28.</citation>
    <PMID>23018877</PMID>
  </reference>
  <reference>
    <citation>Sato M, Hwang DM, Waddell TK, Singer LG, Keshavjee S. Progression pattern of restrictive allograft syndrome after lung transplantation. J Heart Lung Transplant. 2013 Jan;32(1):23-30. doi: 10.1016/j.healun.2012.09.026. Erratum in: J Heart Lung Transplant. 2013 Jun;32(6):664-6.</citation>
    <PMID>23260703</PMID>
  </reference>
  <reference>
    <citation>Sato M, Waddell TK, Wagnetz U, Roberts HC, Hwang DM, Haroon A, Wagnetz D, Chaparro C, Singer LG, Hutcheon MA, Keshavjee S. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant. 2011 Jul;30(7):735-42. doi: 10.1016/j.healun.2011.01.712. Epub 2011 Mar 17.</citation>
    <PMID>21419659</PMID>
  </reference>
  <reference>
    <citation>Todd JL, Jain R, Pavlisko EN, Finlen Copeland CA, Reynolds JM, Snyder LD, Palmer SM. Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction. Am J Respir Crit Care Med. 2014 Jan 15;189(2):159-66. doi: 10.1164/rccm.201306-1155OC.</citation>
    <PMID>24325429</PMID>
  </reference>
  <reference>
    <citation>Verleden SE, de Jong PA, Ruttens D, Vandermeulen E, van Raemdonck DE, Verschakelen J, Vanaudenaerde BM, Verleden GM, Vos R. Functional and computed tomographic evolution and survival of restrictive allograft syndrome after lung transplantation. J Heart Lung Transplant. 2014 Mar;33(3):270-7. doi: 10.1016/j.healun.2013.12.011. Epub 2013 Dec 17.</citation>
    <PMID>24461432</PMID>
  </reference>
  <reference>
    <citation>Verleden GM, Vos R, Verleden SE, De Wever W, De Vleeschauwer SI, Willems-Widyastuti A, Scheers H, Dupont LJ, Van Raemdonck DE, Vanaudenaerde BM. Survival determinants in lung transplant patients with chronic allograft dysfunction. Transplantation. 2011 Sep 27;92(6):703-8. doi: 10.1097/TP.0b013e31822bf790.</citation>
    <PMID>21836537</PMID>
  </reference>
  <reference>
    <citation>Woodrow JP, Shlobin OA, Barnett SD, Burton N, Nathan SD. Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant. 2010 Oct;29(10):1159-64. doi: 10.1016/j.healun.2010.05.012. Epub 2010 Jun 26.</citation>
    <PMID>20580267</PMID>
  </reference>
  <reference>
    <citation>Verleden SE, Ruttens D, Vandermeulen E, Bellon H, Dubbeldam A, De Wever W, Dupont LJ, Van Raemdonck DE, Vanaudenaerde BM, Verleden GM, Benden C, Vos R. Predictors of survival in restrictive chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant. 2016 Sep;35(9):1078-84. doi: 10.1016/j.healun.2016.03.022. Epub 2016 Apr 16.</citation>
    <PMID>27212563</PMID>
  </reference>
  <reference>
    <citation>Verleden SE, Todd JL, Sato M, Palmer SM, Martinu T, Pavlisko EN, Vos R, Neyrinck A, Van Raemdonck D, Saito T, Oishi H, Keshavjee S, Greer M, Warnecke G, Gottlieb J, Haverich A. Impact of CLAD Phenotype on Survival After Lung Retransplantation: A Multicenter Study. Am J Transplant. 2015 Aug;15(8):2223-30. doi: 10.1111/ajt.13281. Epub 2015 Apr 30.</citation>
    <PMID>25940517</PMID>
  </reference>
  <reference>
    <citation>Fernandez IE, Heinzelmann K, Verleden S, Eickelberg O. Characteristic patterns in the fibrotic lung. Comparing idiopathic pulmonary fibrosis with chronic lung allograft dysfunction. Ann Am Thorac Soc. 2015 Mar;12 Suppl 1:S34-41. doi: 10.1513/AnnalsATS.201410-476MG. Review.</citation>
    <PMID>25830833</PMID>
  </reference>
  <reference>
    <citation>Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, Cogan JD, Vulto I, Xie M, Qi X, Tuder RM, Phillips JA 3rd, Lansdorp PM, Loyd JE, Armanios MY. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13051-6. doi: 10.1073/pnas.0804280105. Epub 2008 Aug 27.</citation>
    <PMID>18753630</PMID>
  </reference>
  <reference>
    <citation>Vos R, Verleden SE, Ruttens D, Vandermeulen E, Yserbyt J, Dupont LJ, Van Raemdonck DE, De Raedt N, Gheysens O, De Jong PA, Verleden GM, Vanaudenaerde BM. Pirfenidone: a potential new therapy for restrictive allograft syndrome? Am J Transplant. 2013 Nov;13(11):3035-40. doi: 10.1111/ajt.12474. Epub 2013 Sep 18.</citation>
    <PMID>24102752</PMID>
  </reference>
  <reference>
    <citation>Suhling H, Bollmann B, Gottlieb J. Nintedanib in restrictive chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant. 2016 Jul;35(7):939-40. doi: 10.1016/j.healun.2016.01.1220. Epub 2016 Feb 9.</citation>
    <PMID>26996931</PMID>
  </reference>
  <reference>
    <citation>Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res. 2016 Jan 12;3(1):e000105. doi: 10.1136/bmjresp-2015-000105. eCollection 2016.</citation>
    <PMID>26835133</PMID>
  </reference>
  <reference>
    <citation>Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, Chen D, Schiopu E, Tagliaferri M, Seibold JR, Gorina E. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. J Rheumatol. 2016 Sep;43(9):1672-9. doi: 10.3899/jrheum.151322. Epub 2016 Jul 1.</citation>
    <PMID>27370878</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2017</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

